Adverse Events Reporting in Clinical Trial Publications: MPIP Best Practice Recommendations





The interactive transcript could not be loaded.


Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 21, 2017

Jesse Berlin, ScD, VP and Global Head of Epidemiology, Johnson & Johnson, co-author of “Recommendations to Improve Adverse Event Reporting in Clinical Trial Publications: A Joint Pharmaceutical Industry/Journal Editor Perspective,” provides an insightful overview of this work (BMJ 2016;355:i5078). The recommendations provided in this publication help authors better identify, communicate, and display clinically relevant adverse event (AE) information.

By viewing this webinar, you will learn about:

· Insights gleaned from clinical investigators, journal editors, and biopharmaceutical industry experts involved in the reporting of AE data
· The importance of “clinical relevance” in AE reporting
· 5 best practice recommendations for AE reporting in medical publications, plus practical examples.
· How these recommendations complement existing guidelines for AE reporting

Insights and understanding gained from medical journal editors have been critical to driving improvements in transparency and credibility of industry-sponsored research publications. This webinar is part of an ongoing effort by MPIP to broaden the conversation and engage a wider audience in the effort to continue improvements and promote adoption of best practices.

Comments are disabled for this video.
When autoplay is enabled, a suggested video will automatically play next.

Up next

to add this to Watch Later

Add to

Loading playlists...